1 completed, 1 withdrawn. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Ayman Saad: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant Avatrombopag - Platelet Disorder | Phase 2 | Withdrawn | Ayman Saad | 2022-12-01 | 2021-12-09 | |
| Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide. - Hematologic Neoplasms, Graft-Versus-Host Disease | Not applicable | Completed | Ayman Saad | 7 | 2014-10-09 | 2019-04-25 |
Blood Platelet Disorders (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1)
avatrombopag (1)
United States (1)